Navigation Links
Cardioxyl Pharmaceuticals Presents Data On Its Clinical Candidate, CXL-1020, at the 60th Annual American College of Cardiology Scientific Session
Date:4/4/2011

asing heart rate.  However, unlike SNP, CXL-1020 also showed significantly improved heart muscle contraction (inotropy) and relaxation (lusitropy). Moreover, study findings reported that the effects of CXL-1020 were independent from Beta-Adrenergic Receptor and ACE-inhibitor pathways.  Compared to the inotrope dobutamine , CXL-1020 significantly reduced after-load, stroke work and energetic demand, demonstrating its unique, energetically favorable profile.  The researchers conclude that CXL-1020, through its unique mechanism of action, improves heart function in a manner distinct from nitrovasodilators, and that its efficacy will not be reduced with either beta-blockers or ACE inhibitors, medicines commonly prescribed for patients with heart failure.

A Phase I/IIa First in Man Safety and Tolerability Study of a Novel HNO Donor, CXL-1020, in Patients with Stable Congestive Heart Failure. Monday, April 4, 2011; 9:30 a.m. – 12:30 p.m., Ernest N. Morial Convention Center, Hall F; Poster Board #42

The data presented in this poster demonstrates the safety and tolerability of the novel treatment, CXL-1020, in stable congestive heart failure (CHF) patients.  In the double-blind, placebo controlled, randomized, dose escalation study, two cohorts of patients received four sequentially increasing four-hour infusions, at half-log dose increments between 0.1-30 microgram/kg/min with a randomly interspersed placebo. Patient safety was monitored throughout the study. Researchers also evaluated the plasma and urine pharmacokinetics (PK) during treatment and up to 24 hours post dosing.  The results show that CXL-1020 was well tolerated at doses up to 10 microgram/kg/min with no significant change in heart rate or systolic blood pressure, no decrease in kidney function, and no increase in ventricular ectopy.  The PK of CXL-1020 and its by-product were dose-proportional, and greater than 90 percent of the by-product was recovere
'/>"/>

SOURCE Cardioxyl Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Cardioxyl Pharmaceuticals Initiates Dose-Defining Phase IIa Study of Its Lead Candidate, CXL-1020, in Heart Failure Patients
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
6. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
7. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
8. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
9. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
10. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
11. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... 26, 2014 China Nepstar Chain Drugstore Ltd. (NYSE: ... leading retail drugstore chain in China based on the ... financial results for the third quarter ended September 30, 2014. ... , Same store sales increased by 8.1% compared ... increased by 8.1% to RMB738.3 million (US$120.3 million) compared to ...
(Date:11/24/2014)... 2014 Juno Therapeutics today announced that ... the company,s JCAR015 chimeric antigen receptor product candidate. ... or refractory B-cell acute lymphoblastic leukemia and was ... Cancer Center, where Phase 1 clinical trials are ... is important news for patients who may benefit ...
(Date:11/24/2014)... Nov. 24, 2014  Marta Rendon, MD, founder of the ... Raton , FL and international key opinion leader in dermatology, ... the United States to attend the international ... Turkey . Here, at this gathering of over 600 ... renowned facial plastic surgery experts from Asia ...
Breaking Medicine Technology:China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 2China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 3China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 4China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 5China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 6China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 7China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 8China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 9China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 10China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 11Juno T Cell Therapy For Leukemia Granted FDA Breakthrough Therapy Designation 2Juno T Cell Therapy For Leukemia Granted FDA Breakthrough Therapy Designation 3Marta Rendon, MD Selected To Attend Prestigious, Global Aesthetic Experts Summit! 2Marta Rendon, MD Selected To Attend Prestigious, Global Aesthetic Experts Summit! 3
... ArjoHuntleigh, Inc. is pleased to announce that it ... with HealthTrust Purchasing Group, L.P. (HealthTrust). The agreement, ... take advantage of special pricing and terms for ... for the prevention of deep vein thrombosis (DVT). ...
... 1, 2011 /PRNewswire-Asia-FirstCall/ -- China Medical Technologies, Inc. (the ... advanced in-vitro diagnostic ("IVD") company, today announced that it ... fiscal quarter ended September 30, 2011 ("2Q FY2011") before ... The Company,s senior management will host an earnings ...
Cached Medicine Technology:ArjoHuntleigh Awarded Vascular Compression Contract With HealthTrust Purchasing Group 2China Medical Technologies to Announce Results for the Second Fiscal Quarter Ended September 30, 2011 on November 18, 2011 2
(Date:11/26/2014)... 26, 2014 Bunion Bootie, the newest ... in an early celebration of the early holiday shopping ... offered at the promotional price of $29.95 each (normally ... addition to any automatic discounts applied when buying more ... website for complete details. It’s simple: purchasing more ...
(Date:11/26/2014)... 26, 2014 News Facts , ... capabilities at RSNA 2014 in Chicago. The company ... share diagnostic images, photos, videos and documents found ... #8107 will learn more about these innovative medical ... and partner initiatives – that enable more informed ...
(Date:11/26/2014)... (HealthDay News) -- Youngsters who enter puberty early are ... Early puberty was linked with a number of ... high anxiety levels, according to the researchers. Early puberty ... with family and peers, and having friends who were ... Although the study found an association between early puberty ...
(Date:11/26/2014)... of emergency department visits in the United States rose from ... in 2011, according to the U.S. Centers for Disease Control ... were going to ERs with non-urgent medical needs: 96 percent ... hours of arriving at the ER. In 2010, that number ... of patients arrived at the ER after normal business hours ...
(Date:11/26/2014)... HealthDay Reporter TUESDAY, Nov. 25, 2014 (HealthDay ... disrupt the makeup of bacteria in the digestive system, potentially ... new study suggests. The research doesn,t confirm that ... and study authors aren,t recommending that anyone stop taking the ... used at the lowest dose that provides adequate relief of ...
Breaking Medicine News(10 mins):Health News:Bunion Bootie Temporarily Lowering Prices for Holiday Shopping, Starting Today! 2Health News:Perceptive Software to Demonstrate New Medical Content Management Features and Capabilities at RSNA 2014 2Health News:Perceptive Software to Demonstrate New Medical Content Management Features and Capabilities at RSNA 2014 3Health News:Early Puberty Linked to Increased Risk of Depression in Teens 2Health News:ER Visits on the Rise, Study Reports 2Health News:Could Popular Heartburn Drugs Upset Your 'Good' Gut Bugs? 2Health News:Could Popular Heartburn Drugs Upset Your 'Good' Gut Bugs? 3
... Persons treated with Interferon (IFN)to treat chronic hepatitis C ... phase itself//. Retinopathy can develop within two weeks from commencement ... in the journal Investigative Ophthalmology & Visual Science (IOVS)in the ... in Japan gauged the changes in diameter of ...
... more daughters and no sons, may have a greater risk ... team of Israeli researchers compared families of men diagnosed with ... daughters and risk of prostate cancer were related. ... may be a link but the factors responsible for prostate ...
... a little gadget that can be used for 15 minutes ... device, developed by New York based company Helicor, is under ... users to lower their own heartbeat by regulated deep breathing, ... device, also on trial for several other conditions including anxiety ...
... in maintaining weight and a healthy lifestyle. On the same ... and diuretics are superfluous with no proven benefits. , ... alcohol as a temporary measure to freshen up the kidneys ... to pump the body with more antioxidants. Drinking lots of ...
... a premature baby is up for women who have ... eliminate precancerous cells, called LEEP or loop// incision, researchers ... a study involving 5000 women, researchers said that nearly ... incision was avoided. Babies born prematurely are seen battling ...
... girls might want to have another look at that ... to recent studies, teenage girls who read articles on ... prone to resort to drastic weight reducing techniques such ... who don’t. ,The study, published in Pediatrics' January ...
Cached Medicine News:Health News:Gender Of Children May Be Linked To Risk Of Prostate Cancer 2Health News:Drop That Glossy, Girl! 2
... Our variable volume Finnpipette ... in a high performance pipette. ... colour-coded volume range, ensures quality, ... identification of the volume range ...
... Reference Series 2000 Pipette is a synonym ... compact and robust design, and superior operating ... to operate the measuring stroke and blow-out ... Product features: Eppendorf "pipette/tip" system ensures ...
Pipetman P is a fully adjustable, air-displacement pipette with the selected volume shown on a digital indicator (volumeter). Eight models cover the full range of volumes from 0.2 L to 10 mL....
... Intersurgical Incorporated manufactures high ... and moisture exchangers, ventilator ... hand-held nebulizers and an ... and connectors for anesthesia ...
Medicine Products: